Oncolytics Biotech Inc. (ONCY)

NASDAQ: ONCY · Real-Time Price · USD

0.5600

+0.0038 (0.68%)

Apr 28, 2025, 4:00 PM EDT - Market closed

Oncolytics Biotech Employees

Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.

Employees

28

Change

-1

Growth

-3.45%

Revenue / Employee

n/a

Profits / Employee

-$787,092

Market Cap

48.16M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	28	-1	-3.45%
Dec 31, 2022	29	3	11.54%
Dec 31, 2021	26	1	4.00%
Dec 31, 2020	25	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

ONCY News

4 days ago - Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action - PRNewsWire
18 days ago - Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital - PRNewsWire
18 days ago - Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers - PRNewsWire
7 weeks ago - Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript - Seeking Alpha
7 weeks ago - Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 - PRNewsWire
2 months ago - Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights - PRNewsWire
2 months ago - Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 - PRNewsWire
2 months ago - Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer - PRNewsWire